Clinical Trial

Safety and Effectiveness Study of Dragonfly System for Functional Mitral Regurgitation

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 29, 2022 (before its estimated September 30, 2023 completion). Its status may not reflect the trial's current state.
Summary
To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe (3+) or severe (4+) functional mitral regurgitation (FMR) who remained clinically symptomatic after guideline-directed medical treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-02-01; most recent amendment 2022-03-26.
Status change: Not Yet Recruiting → Recruiting 2022-03-26
Trial Details
NCT Number NCT04733404
Lead Sponsor Hangzhou Valgen Medtech Co., Ltd
Conditions Mitral Regurgitation Functional
Enrollment 120 participants
Start Date 2022-03-12
Primary Completion 2023-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2022-03-29